Advanced search
Publication Cover
Lung Cancer: Targets and Therapy Volume 13, 2022 - Issue
Submit an article Journal homepage
147
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib

Shannon S Zhang1 University of California Irvine School of Medicine, Department of Medicine, Orange, CA, USAORCID Iconhttps://orcid.org/0000-0003-3157-5598
ORCID Icon &
Sai-Hong Ignatius Ou1 University of California Irvine School of Medicine, Department of Medicine, Orange, CA, USA;2 Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1764-4975
ORCID Icon
Pages 23-31 | Published online: 26 Apr 2022

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.